Monopar Therapeutics Inc. Operating Lease, Expense
Monopar Therapeutics Inc. (MNPR) reported Operating Lease, Expense of $54.96 thousand for the 12-month period ending 2021-12-31, per its 10-K filed 2022-03-24.
Discontinued › Expense Statement › Operating Expenses
us-gaap:OperatingLeaseExpense · last filed 2022-03-24
- Monopar Therapeutics Inc. operating lease, expense for the quarter ending 2021-12-31 was $13.46K, a 1.54% decline year-over-year.
- Monopar Therapeutics Inc. operating lease, expense for the quarter ending 2021-09-30 was $13.47K, a 0.03% increase year-over-year.
- Monopar Therapeutics Inc. operating lease, expense for the quarter ending 2021-06-30 was $14.57K, a 0.34% decline year-over-year.
- Monopar Therapeutics Inc. operating lease, expense for the quarter ending 2021-03-31 was $13.46K, a 0.16% decline year-over-year.
- Monopar Therapeutics Inc. operating lease, expense for fiscal 2021 was $54.96K, a 0.50% decline from fiscal 2020.
- Monopar Therapeutics Inc. operating lease, expense for fiscal 2020 was $55.24K, a 6.45% increase from fiscal 2019.
- Monopar Therapeutics Inc. operating lease, expense for fiscal 2019 was $51.89K, a 27.82% increase from fiscal 2018.
- Monopar Therapeutics Inc. operating lease, expense for fiscal 2018 was $40.59K.
| Period end | Operating Lease, Expense 3 month | Operating Lease, Expense 3 month as first filed | Operating Lease, Expense 6 month | Operating Lease, Expense 9 month | Operating Lease, Expense 12 month |
|---|---|---|---|---|---|
| 2021-12-31 | $13.46K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-24 | $26.93K derived: sum of 2 quarters · filed 2022-03-24 | $41.50K derived: sum of 3 quarters · filed 2022-03-24 | $54.96K 10-K · filed 2022-03-24 | |
| 2021-09-30 | $13.47K 10-Q · filed 2021-11-12 | $28.04K derived: sum of 2 quarters · filed 2021-11-12 | $41.50K 10-Q · filed 2021-11-12 | $55.17K derived: sum of 4 quarters · filed 2022-03-24 | |
| 2021-06-30 | $14.57K 10-Q · filed 2021-08-12 | $28.03K 10-Q · filed 2021-08-12 | $41.70K derived: sum of 3 quarters · filed 2022-03-24 | $55.17K derived: sum of 4 quarters · filed 2022-03-24 | |
| 2021-03-31 | $13.46K 10-Q · filed 2021-05-13 | $27.13K derived: sum of 2 quarters · filed 2022-03-24 | $40.59K derived: sum of 3 quarters · filed 2022-03-24 | $55.22K derived: sum of 4 quarters · filed 2022-03-24 | |
| 2020-12-31 | $13.67K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-24 | $27.13K derived: sum of 2 quarters · filed 2022-03-24 | $41.75K derived: sum of 3 quarters · filed 2022-03-24 | $55.24K 10-K · filed 2022-03-24 | |
| 2020-09-30 | $13.46K 10-Q · filed 2021-11-12 | $28.08K derived: sum of 2 quarters · filed 2021-11-12 | $41.56K 10-Q · filed 2021-11-12 | $55.03K derived: sum of 4 quarters · filed 2021-11-12 | |
| 2020-06-30 | $14.62K 10-Q · filed 2021-08-12 | $28.10K 10-Q · filed 2021-08-12 | $41.56K derived: sum of 3 quarters · filed 2021-08-12 | $55.03K derived: sum of 4 quarters · filed 2021-08-12 | |
| 2020-03-31 | $13.48K 10-Q · filed 2021-05-13 | $26.94K derived: sum of 2 quarters · filed 2021-05-13 | $40.41K derived: sum of 3 quarters · filed 2021-05-13 | $53.87K derived: sum of 4 quarters · filed 2021-05-13 | |
| 2019-12-31 | $13.46K derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-25 | $26.92K derived: sum of 2 quarters · filed 2021-03-25 | $40.38K derived: sum of 3 quarters · filed 2021-03-25 | $51.89K 10-K · filed 2021-03-25 | |
| 2019-09-30 | $13.46K 10-Q · filed 2020-11-12 | $26.92K derived: sum of 2 quarters · filed 2020-11-12 | $38.43K 10-Q · filed 2020-11-12 | $45.98K derived: sum of 4 quarters · filed 2020-11-12 | |
| 2019-06-30 | $13.46K 10-Q · filed 2020-08-06 | $24.96K 10-Q · filed 2020-08-06 | $32.52K derived: sum of 3 quarters · filed 2020-08-06 | $42.97K derived: sum of 4 quarters · filed 2020-08-06 | |
| 2019-03-31 | $11.50K 10-Q · filed 2020-05-07 | $19.06K derived: sum of 2 quarters · filed 2020-05-07 | $29.51K derived: sum of 3 quarters · filed 2020-05-07 | $39.96K derived: sum of 4 quarters · filed 2020-05-07 | |
| 2018-12-31 | $7.56K derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-27 | $18.01K derived: sum of 2 quarters · filed 2020-03-27 | $28.46K derived: sum of 3 quarters · filed 2020-03-27 | $40.59K 10-K · filed 2020-03-27 | |
| 2018-09-30 | $10.45K derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-12 | $20.90K derived: sum of 2 quarters · filed 2019-11-12 | $33.04K 10-Q · filed 2019-11-12 | ||
| 2018-06-30 | $10.45K 10-Q · filed 2019-11-12 | $9.34K 10-Q · filed 2019-08-08 | $22.59K 10-Q · filed 2019-08-08 | ||
| 2018-03-31 | $13.24K 10-Q · filed 2019-05-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CytomX Therapeutics, Inc. (CTMX) | United States | $0.598B | -10.25 |
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| CorMedix Inc. (CRMD) | United States | $0.605B | 3.25 |
| Aquestive Therapeutics, Inc. (AQST) | United States | $0.606B | -6.67 |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| Indaptus Therapeutics, Inc. (INDP) | United States | $0.537B |